Transcript EuropaBio Explains

Explains
The Joint Research Council’s
Bio4EU Report
Dr. Johan Vanhemelrijck
Secretary General of EuropaBio
First Glance
Is Europe doing well?
• Healthcare Biotech:
The number of biopharmaceuticals on the
market has more than doubled in the last
ten years.
• Agricultural Biotech:
Modern Biotechnology is related to up to
20% of the input sector’s turnover.
• Industrial Biotech:
The EU produces about 75% of enzymes
worldwide.
EuropaBio, the European Association for
Bioindustries, has 78 direct corporate
members, 12 associate members and 5
bioregions as well as 25 national
biotechnology associations representing
some 1800 small and medium sized
enterprises involved in research and
development, testing, manufacturing and
distribution of biotechnology products.
www.europabio.org
What is Bio4EU?
The Joint Research Council’s Bio4EU Study:
• A comprehensive socio-economic impact
study of biotechnology in Europe.
• Input for the Mid-Term Policy Review on
the EU’s Life Science and Biotechnology
Strategy (2002).
• Published on 20 April 2007 at the Bio4EU
Symposium in Brussels.
Bio4EU in-Depth
• Biotech’s Contribution to EU Policy Goals
• Survey of the Biotech industry
– Healthcare
– Agriculture
– Industrial
•
•
•
•
Biotech R&D
Biotech & Employment
The EU policy based on Bio4EU
EuropaBio’s Diagnosis
EU Policy Goals & Biotech
• Competitiveness:
– Biotech enhances the efficiency of production
processes.
• Economic Growth:
– Biotech enables the provision of new and improved
products.
• Employment:
– Biotech jobs appear to be higher qualitatively and
more productive.
Overall contribution: 1.56% to the EU’s Gross
Value Added (GVA).
Healthcare Biotech
Turnover of modern biotech healthcare products in
the EU (2005)
Diagnostics
1700 million
EUR
Recomcinant
vaccines 259
million EUR
Biopharmaceuti
cals 11340
million EUR
Source: Bio4EU Draft Final Analysis report
Healthcare
Biopharmaceuticals
• Biopharmaceutical companies rose from
37 (1996) to 143 (2005).
• 78% of EU biotech products are
biopharmaceuticals.
• Biopharmaceuticals hold a 9% share of
the EU pharmaceutical market.
• Growth rates in biopharmaceuticals are
twice as high as non-biotech.
Healthcare
Biopharmaceuticals
Examples include:
•
•
•
•
Cancer treatment (antibodies);
Diabetes (insulin);
Multiple sclerosis (innovative treatments);
Gaucher's disease (enzyme replacement).
Healthcare
Vaccines
• Safety, e.g. biotech vaccines made with
only the proteins of pathogens which
trigger the immune reaction.
• The revenues for recombinant vaccines
in the EU have grown from EUR 65
million (1996) to EUR 259 million
(2005).
Examples include:
• Hepatitis B vaccines
Healthcare
Diagnostics
• In vitro diagnostics (IVD) are methods for
testing specimens taken from the body
• Biotech IVD consist of about 30% of turnover
from all IVD in the EU in 2005.
Innovative examples include:
• HIV detection using nucleic-acid-based tests
• Cardiac diagnostic assays to detect
biomarkers associated with heart attacks.
Healthcare
Outlook
Biotech offers healthcare:
• unique therapeutic and diagnostic
solutions;
• unlimited supplies of potentially safer
products;
• superior therapeutic and diagnostic
approaches;
• the potential for cost reduction.
Agri-food Biotech
Agri-Food
Agri-food sub-sectors using biotech
Fish breeding and
hatcheries .8%
Agri-Food Sector
Manufacture of other
chemical products 9%
Animal husbandry service
activities 6%
Veterinary products &
services 21%
Diagnostics in primary
production and the food
chain 2%
Nursery flowers and plans
26%
Seeds and planting stock
35%
Biotech represents 2% of the Agri-food sector
Source: Bio4EU Draft Final Analysis report
Agri-Food
Agri-food Biotech
• Molecular markers are applied in research
in almost all plant-related sectors for hybrid
variety development.
• Micropropagation, for cloning identical
offspring in large numbers, is used for the
multiplication of ornamental plants.
– 60% is used for propagating orchids
commercially.
Agri-Food
Agri-food Biotech
• Genetic Modification - only 2 Bt maize GM
crops have been approved for cultivation in
the EU.
• Studies in Spain show an average
increase in gross margin of 85 Euro per ha,
this is 12% higher than non-BT maize
production.
• Economic benefits vary from region to
region depending on insect pressure and
other factors.
Agri-Food
Agri-food Biotech
Adoption Rates - share of GM
maize area out of total grain
maize area
Data Source
EU 25
0.83%
EU Commission / Clive JamesISAAA
USA
South Africa
The World
52%
17%
14%
USDA
Clive James-ISAAA
FAOSTAT / Clive JamesISAAA
Note: In the USA GM maize can be either Bt maize, Herbicide tolerant (HT) maize
or HT/Bt maize, while in the EU is only Bt maize
• The EU is falling behind the rest of the world in
GM crop adoption
Source:Bio4EU Draft Final Analysis report
Agri-Food
Agri-food Biotech
• Biotech is used in veterinary and food
diagnostics, such as in the detection of
BSE & Salmonella.
• For BSE, biotech provides the only
method for the rapid processing of
samples and diagnosis, to comply with
EU legislation, reducing the risk of
contamination and increasing consumer
trust in beef.
Agri-Food
Agri-food Biotech
Other examples include:
• diagnostic veterinary vaccines, for
pseudorabies eradication;
• enzymes for food production, for in fruit
juice production.
Agri-Food
Outlook
Agri-food biotech can:
• increase crop efficiency;
• monitor and control some of the most
important animal-to-human disease
transfers and food safety concerns.
• reduce costs of applications in the agrifood industry;
• real benefits for public health.
Industrial Biotech
Global and EU distribution of enzyme
producing companies
France 17
Germany 11
Finland 1
Ireland 1
Rest of the world 21
Denmark 5
Italy 6
EU
USA 21
Czech Republic 4
Netherlands 3
Cyprus 1
Bulgaria 1
The EU has 75 enzyme
producing companies
Poland 1
Belgium 5
UK 4
Source: Bio4EU Draft Final Analysis report
Spain 13
Industrial
Industrial Biotech
• About 45% of all manufacturing sectors
use modern biotechnology.
Biotech contributes to sustainability by:
• Reducing the levels of chemicals and
energy for input.
• Reducing emissions into the air or water.
• Reducing the consumption of water in
manufacturing.
• Reducing the ecological footprint of
industry.
Industrial
Enzymes
Currently limited to specific processes and
enzyme production for individual steps in
the manufacturing production process.
Examples of enzyme use include:
• textile finishing and de-sizing cotton;
• pulp bleaching for pulp and paper
manufacturing;
Industrial
Enzyme uses
• detergents for laundry and automatic
dishwashers;
• polymers are biotech-based in some
chemical products;
• antibiotics, amino acids and drug
compounds have biotech production
processes.
Industrial
BioFuels
• 100% replacement of gasoline with
bioethanol would lower GHG emissions by
around 4%.
Biofuels offer environmental benefits:
• due to the switch to renewable input
materials;
• due to lower energy demand from industrial
processes.
Industrial
BioFuels
• Biofuels, especially bioethanol, have
potential to diversify energy sources,
increase renewable energy sources and
reduce GHG emissions.
• Research is focusing bioethanol, from nonfood feedstock or biomass.
• Biotech processes are being researched for
the production of other biofuels like
Biodiesel and Biobutanol.
Industrial
Outlook
Industrial Biotech:
• increases labour productivity by 10% to 20%
compared with conventional processes;
• reduces energy and water consumption and
emissions, including greenhouse gases;
• offers more sustainable methods to produce
everyday necessities from energy to clothing.
Biotech R&D
• The EU is strong in terms of researchers
and biotech research centres.
• However, the EU’s capacity to apply this
knowledge to products that lead to
commercially viable businesses is lower
than in the USA.
Biotech & Employment
Biotech-related processes:
• Create of higher qualified jobs.
However,
• There is limited data availability and
difficulties in including indirect
employment effects.
• Some newly generated biotech jobs take
the place of existing ones.
The EU policy priorities from
Bio4EU
The EU Commission’s action plan:
1. Promote research and market
development.
2. Facilitate knowledge transfer and
innovation from the science base to
industry.
The EU policy priorities from
Bio4EU
3. Encourage informed societal debates.
4. Ensure a sustainable contribution of
modern biotechnology to agriculture.
5. Improve the implementation of the
legislation at Member State level.
Diagnosis
• The Bio4EU Study is a welcome and an
extensive contribution to the Mid-Term
Policy Review.
• The refocused actions proposed by the
Commission, as a result of the Bio4EU
Study, are an important step towards
building the bio-economy.
Diagnosis
• However, it is essential that the important
information in the Bio4EU Study not go to
waste.
• There is a lack of implementation of the
EU biotech strategy by a number of
Member States.
• The new action plan for biotechnology
should to be implemented evenly and
coherently throughout Europe.
Diagnosis
Ministers must realise that they are the
key solution to reduce the fragmentation
by implementing the strategy in a
coherent and timely manner. This will
take the science out of the labs and bring
it to society, helping to meet our needs be
they medical, agricultural, industrial or
environmental.
Thank you
To learn more about
EuropaBio:
www.europabio.org
Citations
JRC Bio4EU Reports
• Synthesis Report - Consequences, Opportunities and Challenges of
Modern Biotechnology for Europe
•
Analysis Report - Contributions of modern biotechnology to European
policy objectives (DG JRC/IPTS) - Draft Final Version, 31 January 2007
Both reports can be found at http://bio4eu.jrc.es/
EU Commission Documents
•
‘EU puts emphasis on innovation in the field of biotechnology’ EU
Commission Press Release of 11/04/2007
http://europa.eu/rapid/pressReleasesAction.do?reference=IP/07/484&form
at=HTML&aged=0&language=EN&guiLanguage=en